Aarti Pharmalabs Schedules Board Meeting on February 5 to Approve Q3 FY25 Financial Results and Interim Dividend

Mumbai, January 28, 2025 – Aarti Pharmalabs Limited (NSE: AARTIPHARM, ISIN: INE0LRU01027) has announced that its Board of Directors will meet on February 5, 2025, to consider and approve the audited standalone and consolidated financial results for Q3 FY25, alongside the declaration of an interim dividend.

Key Details of the Board Meeting​

• Date: February 5, 2025
• Agenda Items:
  • Approval of audited standalone and consolidated financial results for Q3 FY25 (quarter ended December 31, 2024).
  • Declaration of interim dividend.
  • Discussion on other business matters.
• Trading Window Closure:
  • As per SEBI's insider trading regulations, the trading window remains closed until 48 hours after the financial results are disclosed.

Market Expectations​

• Investors will closely watch the company's revenue growth, profit margins, and outlook for FY25, particularly in the pharmaceutical and specialty chemicals sector.
• The announcement of an interim dividend is expected to boost investor sentiment and provide insights into the company's cash flow and profitability.

Strategic Significance​

With the growing demand for specialty chemicals and active pharmaceutical ingredients (APIs), Aarti Pharmalabs' financial performance will be a key indicator of industry trends and future growth potential.